|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Design and Optimization of the Lining of a Tunnel in the Presence of Expansive Clay Levels 显示文摘 | PE'REZ-ROMERO J OTEO C S DE LA FUENTE P | 2007 | Tunnelling and Underground Space Technology2007，22，1： | 1 |
| 2 | Tacrolimus pharmacokinet- ics in the early post - liver transplantation period and clinical applicabil- ity via Bayesian Prediction显示文摘 | Itziar Oteo John C Lukas Nerea Leal | 2013 | Eur J C lin Pharmacol2013，69，： | 1 |
| 3 | Extended-spectrum beta-lacta- mase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types,including ST10 complex/A, ST23 eomplex/A and ST131/B2显示文摘 | Oteo J Diestra K Juan C | 2009 | Int J Antimierob Agents2009，34，2： | 1 |
| 4 | Apoptosis, of alloreactire T cell in liver allograft during tolerance induction显示文摘 | Meyer D Thoruarth M Oteo C | 1999 | Transplant proc1999，31，12： | 1 |
| 5 | Design and optimization of the lining of a tunnel in the presence of expansive clay levels 显示文摘 | PEREZ-ROMERO J OTEO C S de la FUENTE P | 2007 | Tunnelling and Underground Space Technology2007，22，1： | 1 |
| 6 | Trends in antimicrobial resistance in 3469 enterococci isolated from blood (EARSS experience 2001 -06, Spain) : Increasing ampicillin resistance in Enterococcus faecium 显示文摘 | Oteo J Cuevas O Navarre C | 2007 | J Antimicrob Chemother2007，21，： | 1 |
| 7 | Genotypic diver- sity of imipenem resistant isolates of Acinetobacter baumannii in Spain显示文摘 | Oteo J Garcia-Est6banez C Miguelcifiez S | 2007 | J Infect2007，55，3： | 1 |
| 8 | Urban Tunnels in Hard Soils显示文摘 | Oteo C S | 1993 | Geotechnical Engineering of Hard Soils/Soft Rocks1993，3，： | 1 |
| 9 | Trends in antimicrobial resistance in 3469 Enterococci isolated from blood( EARSS experience 2001 -06, Spain) :increasing ampicillin resistance in Enterococcus faecium显示文摘 | Oteo J Cuevas O Navarro C | 2007 | J Antimicrob Chemother2007，59，5： | 1 |
| 10 | Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the com- munity, long-term care facilities, and hospital institutions显示文摘 | Oteo J Navarro C Cercenado E | 2006 | J Clin Mierobio12006，44，7： | 1 |
| 11 | Clinical utility of maraviroc 显示文摘 | Parra J Portilla J Pulido F Sanchez-de LRR Alonso- Vitlaverde C Berenguer J Blanco JL Domingo P Dronda F Galera C Gutierrez F Kindelan JM Knobel H Leal M Lopez-Aldeguer J Marino A Miralles C Molto J Or- tega E Oteo JA | 2011 | Clin Drug Investig2011，31，8： | 1 |
| 12 | Genotypic diversity of imipenem resistant isolates of Acinetobacter baumannii in Spain 显示文摘 | OTEO J GARCIA-ESTEBANEZ C MIGELANEZ S | 2007 | J Infect2007，55，3： | 1 |
| 13 | Prospective application of a bleeding and ischemic risks-adjusted antithrombotic protocol in elderly patients revascularized with everolimus-eluting stents:EPIC05-Sierra75 study显示文摘OBJECTIVES Elderly patients show a higher incidence of ischemic and bleeding events after percutaneous transluminal coron-ary intervention(PCI).We sought to investigate outcomes in elderly patients treated with antithrombotic strategy guided by bleeding and ischemic risks after revascularization with last generation everolimus-eluting stent(EES).METHODS Prospective multicenter registry including patients over 75 years revascularized with EES and antithrombotic ther-apy guided by clinical presentation,PCI complexity and PRECISE DAPT score.Co-primary safety endpoints were:(1)composite of cardiac death,myocardial infarction and stent thrombosis and;(2)bleeding(BARC 2-5).Primary efficacy endpoint was target lesion revascularization.A matched group of patients revascularized with current drug-eluting stents and no such tailored antith-rombotic therapy was used as control.RESULTS Finally,1064 patients were included in SIERRA-75 cohort,80.8±4.2 years,36.6%women,71%acute coronary syn-dromes(ACS)and 53.6%complex PCI.Co-primary safety endpoint of major adverse cardiovascular events was met in 6.2%,co-primary safety endpoint of bleeding in 7.8%and primary efficacy endpoint of TKLR in 1.5%.The multivariable adjusted model showed no significant association of the prescribed short/long dual antiplatelet therapy(DAPT)durations with any endpoint suggesting a well tailored therapy.No stent thrombosis reported in the subgroup with 1-3 months DAPT duration.As compared to control group,bleeding BARC 2-5 was significantly lower in SIERRA-75 group(7.4%vs.10.2%,P=0.04)as well as the net safety-efficacy endpoint(14.3%vs.18.5%,P=0.02).CONCLUSIONS In elderly population,the application of this risks-adjusted antithrombotic protocol after revascularization with last generation EES seems to be associated with an improved prognosis in terms of ischemic and bleeding outcomes. | Jose M de la Torre Hernandez Ramon Lopez Palop Jesus M Jimenez Mazuecos Pilar Carrillo Sáez Alejandro Gutierez-Barrios Eduardo Pinar Belen Cid Luis Fernandez Tamara Garcia Camarero Cristóbal Urbano-Carrillo Juan F Oteo Dominguez Victor A Jimenez Diaz Antonio EGomez Menchero Eladio Galindo Fernández Juan GCórdoba Soriano Raymundo Ocaranza Eduardo ArroyoÚcar Koldobika Garcia San Roman Silvio Leal Ginés Martínez Cáceres Jose A Linares Vicente Georgina Fuertes Ferre Xavier Carrillo Juan CRama Merchán Catia Costa Juan Sanchis Renato Fernandes Alberto Rodrigues Jose M Vegas Valle Hélder Pereira Armando Perez de Prado | 2022 | Journal of Geriatric Cardiology2022，19，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员